Exact peptide identities attached to retained registry observations carrying this condition label.
Coverage-gated living condition brief
Diabetes Mellitus, Type 2 peptide evidence brief
A cited Diabetes Mellitus, Type 2 peptide evidence brief across 33 exact-label ClinicalTrials.gov records, 11 connected profiles, and 8 registry-update years. The label is copied from each retained registry version and does not imply that PeptideScanner has verified a diagnosis, treatment relationship, or study result.
33 selected records.
11 profiles.
2014–2026 in selected records.
Direct collection answer · published August 17, 2026
What peptide evidence does PeptideScanner carry for Diabetes Mellitus, Type 2?
PeptideScanner’s selected collection contains 33 retained ClinicalTrials.gov records carrying the exact condition label “Diabetes Mellitus, Type 2,” connected to 11 peptide profiles across 8 registry-update years.
That answer describes this collection and the exact cited registry observations below. It is not a conclusion about whether any peptide treats Diabetes Mellitus, Type 2, and it is not a safety or efficacy assessment.
Indication intelligence
Selected evidence landscape
Phase labels copied from the retained ClinicalTrials.gov versions.
Overall statuses at each retained observation, not necessarily current today.
Across the connected peptide profiles, PeptideScanner also carries 348 selected PubMed records and 28 selected Drugs@FDA applications. Those records are profile context only; PeptideScanner does not claim they concern Diabetes Mellitus, Type 2 unless their own cited source says so.
Related profile context
Literature connected through these peptide profiles
This is a bounded sample of up to six PubMed bibliography records connected through peptide profiles on this hub, not the total profile literature count above. They are not condition-matched records, and their presence does not establish that they concern Diabetes Mellitus, Type 2.
Albiglutide · source record 2021-02-01
Randomized 52-week Phase 2 Trial of Albiglutide Versus Placebo in Adult Patients With Newly Diagnosed Type 1 Diabetes.
PubMed lists PMID 32219329 in The Journal of clinical endocrinology and metabolism as Clinical Trial, Phase II, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, and 1 more PubMed publication type, with publication-date metadata of 2020-06-01 (day precision). PeptideScanner associated the retained record with the identity slug albiglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Open attributed literature record →Semaglutide · source record 2026-11-12
Semaglutide and alcohol use disorder: An evidence gap India must fill.
PubMed lists PMID 43011941 in Indian journal of psychiatry as Letter, with publication-date metadata of 2026-10-21 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Open attributed literature record →Eloralintide · source record 2026-08-15
Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept.
PubMed lists PMID 41559929 in Diabetes, obesity & metabolism as Journal Article, Randomized Controlled Trial, Clinical Trial, Phase I, Multicenter Study, with publication-date metadata of 2026-01-20 (day precision). PeptideScanner associated the retained record with the identity slug eloralintide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Open attributed literature record →Tirzepatide · source record 2026-11-15
Tirzepatide in Adolescents With Obesity: Research Summary.
PubMed lists PMID 43035094 in JAMA as Journal Article, with publication-date metadata of 2026-11-15 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Open attributed literature record →Dulaglutide · source record 2026-01-27
Dulaglutide (Trulicity) for Type 2 Diabetes Mellitus.
PubMed lists PMID 29094890 in American family physician as Journal Article, with publication-date metadata of 2017-10-15 (day precision). PeptideScanner associated the retained record with the identity slug dulaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Open attributed literature record →Efinopegdutide · source record 2026-11-09
Efinopegdutide: a step towards precision in MASH therapy?
PubMed lists PMID 43003104 in Lancet (London, England) as Journal Article, with publication-date metadata of 2026-11-09 (day precision). PeptideScanner associated the retained record with the identity slug efinopegdutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Open attributed literature record →Collection change ledger
Recently changed records on this condition hub
These events come only from the exact registry records shown on this page. The condition label does not establish a diagnosis, treatment relationship, or scientific agreement.
ClinicalTrials.gov record NCT00838903
PeptideScanner retained ClinicalTrials.gov record NCT00838903 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-01-09, and PeptideScanner's reviewed identity mapping was albiglutide.
- PeptideScanner change date
- November 16, 2026
- Cited source date
- January 9, 2017
- Evidence lane
- Clinical trials
ClinicalTrials.gov record NCT00838916
PeptideScanner retained ClinicalTrials.gov record NCT00838916 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-01-09, and PeptideScanner's reviewed identity mapping was albiglutide.
- PeptideScanner change date
- November 16, 2026
- Cited source date
- January 9, 2017
- Evidence lane
- Clinical trials
ClinicalTrials.gov record NCT00839527
PeptideScanner retained ClinicalTrials.gov record NCT00839527 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-01-09, and PeptideScanner's reviewed identity mapping was albiglutide.
- PeptideScanner change date
- November 16, 2026
- Cited source date
- January 9, 2017
- Evidence lane
- Clinical trials
Exact-record source chronology
Diabetes Mellitus, Type 2 registry timeline
Years come from the last-update date on each retained ClinicalTrials.gov observation. They show source chronology, not when PeptideScanner added the record and not a continuous monitoring guarantee.
2026
15 recordsAmycretin · 2026-11-12
ClinicalTrials.gov record NCT07931495
Not yet recruiting at the retained observation.
Open cited registry record →Semaglutide · 2026-11-12
ClinicalTrials.gov record NCT07931599
Not yet recruiting at the retained observation.
Open cited registry record →Semaglutide · 2026-11-10
ClinicalTrials.gov record NCT07400107
Active, not recruiting at the retained observation.
Open cited registry record →Dulaglutide · 2026-11-05
ClinicalTrials.gov record NCT07668336
Recruiting at the retained observation.
Open cited registry record →Tirzepatide · 2026-11-04
ClinicalTrials.gov record NCT07697391
Recruiting at the retained observation.
Open cited registry record →Tirzepatide · 2026-11-04
ClinicalTrials.gov record NCT07881458
Recruiting at the retained observation.
Open cited registry record →Eloralintide · 2026-11-03
ClinicalTrials.gov record NCT07900633
Not yet recruiting at the retained observation.
Open cited registry record →Eloralintide · 2026-10-09
ClinicalTrials.gov record NCT07215559
Active, not recruiting at the retained observation.
Open cited registry record →Orforglipron · 2026-10-08
ClinicalTrials.gov record NCT07613307
Recruiting at the retained observation.
Open cited registry record →Semaglutide · 2026-10-07
ClinicalTrials.gov record NCT07668388
Recruiting at the retained observation.
Open cited registry record →Semaglutide · 2026-09-30
ClinicalTrials.gov record NCT03596450
Completed at the retained observation.
Open cited registry record →Semaglutide · 2026-09-18
ClinicalTrials.gov record NCT05714683
Not yet recruiting at the retained observation.
Open cited registry record →Semaglutide · 2026-09-11
ClinicalTrials.gov record NCT07415954
Recruiting at the retained observation.
Open cited registry record →Semaglutide · 2026-09-09
ClinicalTrials.gov record NCT03811561
Active, not recruiting at the retained observation.
Open cited registry record →Maridebart cafraglutide · 2026-09-03
ClinicalTrials.gov record NCT07684144
Recruiting at the retained observation.
Open cited registry record →2025
1 recordEfinopegdutide · 2025-04-27
ClinicalTrials.gov record NCT03235219
Completed at the retained observation.
Open cited registry record →2023
1 recordExenatide · 2023-07-20
ClinicalTrials.gov record NCT02981069
Completed at the retained observation.
Open cited registry record →2020
1 recordAlbiglutide · 2020-11-27
ClinicalTrials.gov record NCT02229227
Completed at the retained observation.
Open cited registry record →2019
1 recordSemaglutide · 2019-06-19
ClinicalTrials.gov record NCT03466567
Completed at the retained observation.
Open cited registry record →2018
1 recordSemaglutide · 2018-04-18
ClinicalTrials.gov record NCT02146079
Completed at the retained observation.
Open cited registry record →2017
12 recordsAlbiglutide · 2017-07-21
ClinicalTrials.gov record NCT00938158
Completed at the retained observation.
Open cited registry record →Albiglutide · 2017-06-14
ClinicalTrials.gov record NCT01077505
Completed at the retained observation.
Open cited registry record →Albiglutide · 2017-06-08
ClinicalTrials.gov record NCT01406262
Completed at the retained observation.
Open cited registry record →Semaglutide · 2017-04-04
ClinicalTrials.gov record NCT02022254
Completed at the retained observation.
Open cited registry record →Albiglutide · 2017-02-28
ClinicalTrials.gov record NCT01098539
Completed at the retained observation.
Open cited registry record →Albiglutide · 2017-01-13
ClinicalTrials.gov record NCT01098461
Completed at the retained observation.
Open cited registry record →Albiglutide · 2017-01-11
ClinicalTrials.gov record NCT01475734
Completed at the retained observation.
Open cited registry record →Albiglutide · 2017-01-09
ClinicalTrials.gov record NCT00838903
Completed at the retained observation.
Open cited registry record →Albiglutide · 2017-01-09
ClinicalTrials.gov record NCT00838916
Completed at the retained observation.
Open cited registry record →Albiglutide · 2017-01-09
ClinicalTrials.gov record NCT00839527
Completed at the retained observation.
Open cited registry record →Albiglutide · 2017-01-09
ClinicalTrials.gov record NCT00849017
Completed at the retained observation.
Open cited registry record →Albiglutide · 2017-01-09
ClinicalTrials.gov record NCT00849056
Completed at the retained observation.
Open cited registry record →2014
1 recordLiraglutide · 2014-12-09
ClinicalTrials.gov record NCT01507389
Completed at the retained observation.
Open cited registry record →- Condition matching is limited to exact labels on retained ClinicalTrials.gov v3 observations; PeptideScanner does not merge related diagnoses or synonyms.
- Coverage is selective and historical, not a complete or continuously current account of the registry or PubMed.
- The brief does not synthesize study outcomes, compare interventions, or make safety, efficacy, diagnosis, or treatment claims.